Novo Nordisk has struck a collaboration and licensing deal with U.S. biotech Septerna to develop oral small molecule medicines for obesity, type 2 diabetes and other cardio-metabolic diseases that ...

Novo Nordisk is partnering with the biotech Septerna to develop oral obesity drugs, as it aims for more convenient weight ...

A pronouncement from President Trump about the category drove their share prices down, although not to bargain-basement ...

Zepbound — the brand name for tirzepatide — is the most effective GLP-1 medication for weight loss, according to one study.

Tirzepatide slashed weight by 20%, leading researchers to call this a new “golden age” for weight-loss therapies.

As medications become increasingly popular to support weight loss, not all of them are approved by the U.S. Food and Drug ...

Digital programs incorporating behavioral therapy led to solid reductions in body weight, and did so at lower drug doses.

The best metric is not weight, but a particularly toxic kind of fat.

While the drugs certainly contribute to weight loss and health gains, they also cause a decline in muscle that some doctors ...

For the 2025 outlook, Novo Nordisk now expects 13-21% revenue increase at constant exchange rates (CER). Operating profit is ...

Tirzepatide (trade name Zepbound) promoted greater weight loss in individuals with obesity than did semaglutide (trade name ...

For the first time, scientists have pitted the two most popular weight loss drugs against each other in a direct competition ...